HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bear Stearns Healthcare Conference In Brief

Executive Summary

One Swiss pharma company?: Novartis continues "to indicate to Roche that it might be a good idea for us to sit down and talk and I think as late as last Sunday, the Roche CEO continues to say that it's absolutely out of the question and not on the table," General Manager Kurt Graves says during Bear Stearns healthcare conference in New York City Sept. 17. "I would say it's remained consistent for over a year." Novartis' purchase of a 20% stake in Roche a year ago sparked rumors that Novartis was interested in partnering with its Swiss neighbor (1"The Pink Sheet" May 14, 2001, p. 11)...
Advertisement

Related Content

Novartis Zelnorm Approval: FDA Accepts Overseas History, Active Surveillance
Pfizer To Re-Do Celebrex GI Outcome Study After Pharmacia Merger
Rx Stock Declines Leave Novartis, P&G With More Options
Rx Stock Declines Leave Novartis, P&G With More Options
Celebrex Label Update Has CV Profile Similar To NSAIDs, No New GI Safety
Novartis COX-189 Is Co-Promotion Candidate; Zelnorm Will Not Have Partner
Novartis Gleevec Drug Interaction Program Is Phase IV For GIST Approval
Pfizer Sees Neurontin Exclusivity Through 2002, Pregabalin Filing By Year-End
Advertisement
UsernamePublicRestriction

Register

PS040491

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel